Project Grant HT94252410469
Award Date
5/15/24
Completion Date
5/14/27
Dollars Obligated
$322K
Federal Agency
Defense Health Agency
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Hamden, CT 06511, USA
Similar Awards
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,130,469 to Yale University to uncover the tumor-immune microenvironmental determinants of immunotherapy response in renal cell carcinoma through ex vivo patient-derived models. The research aims to transform health care for Service Members and the American public through innovative and impactful research investigating medical solutions for the battlefield....
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
The federal Project Grant award of $1,009,054.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports research aimed at "Discovery and Therapeutic Targeting of Endogenous Retroviruses in Clear Cell Renal Cell Carcinoma" at Yale University over the period of September 1, 2025 to August 31, 2029. The research project seeks to advance biomedical knowledge and develop innovative treatments for this form of...
This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $1,008,999.00 to Yale University to conduct research focused on "Discovery and Therapeutic Targeting of Endogenous Retroviruses in Clear Cell Renal Cell Carcinoma." The award period runs from September 1, 2025 to August 31, 2029. The research aims to advance the understanding and treatment of clear cell renal cell carcinoma, a type of kidney cancer,...
The Defense Health Agency awarded Yale University a $3,129,087.00 Project Grant on September 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant supports advanced research to develop integrative platforms for cellular immunotherapies against resistant hematopoietic malignancies and solid tumors. Key aims include targeting combinations of gene editing and CAT inhibition to enhance CAR-T cell function, and investigating gene editing coupled with CAT...
The Defense Health Agency has awarded a $1,387,727 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma", will fund research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will investigate innovative approaches to cancer diagnosis,...
This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing treatments...
The Department of the Army Medical Command awarded Yale University a $1,004,997 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund Yale University's pilot development of new forms of chimeric antigen receptor therapies for kidney cancer from August 15, 2021 to August 14, 2024. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,158,989.00 to Yale University to conduct research on optimizing adoptive cellular immunotherapy for rare melanomas. The research project commenced on September 1, 2023 and is scheduled for completion by August 31, 2026. The key objectives of this grant-funded research are to advance innovative medical solutions for rare forms of melanoma that are difficult to...